Published in Cancer Weekly, June 7th, 2005
For the first quarter of 2005, the company reported net income of $30.1 million or $0.28 per share on a fully diluted basis, compared with the first quarter of 2004 net loss of $20.2 million or ($0.24) per share.
The 2005 net income figure includes a nonrecurring gain of $40.9 million, recognizing the extinguishment of a long-term loan due to Genentech, Inc. (DNA) as part of a restructuring of XOMA's arrangement with Genentech with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.